With ISS and Glass Lewis both backing management's slate, the probability of Pacira's nominees winning the vote has increased. Monitor the June 9 meeting outcome; a management win removes near-term activist pressure for a sale and supports continued execution of the 5x30 strategy. A dissident win could accelerate strategic review or sale processes.
Price Chart
Executive Summary
Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FOR all three of Pacira's director nominees and AGAINST all three of DOMA Perpetual Capital Management's nominees at the June 9, 2026 annual meeting. ISS concluded the dissident has not presented a compelling case for change and that Pacira's board has been proactive in refreshment and strategy. This filing is management's solicitation material urging stockholders to support the company's slate ahead of a contested proxy vote.
Key Facts
- ISS recommends voting FOR all three of Pacira's director nominees (Christopher Christie, Samit Hirawat, Thomas Wiggans) and AGAINST all three of DOMA Perpetual's nominees.
- Annual Meeting scheduled for June 9, 2026.
- ISS noted Pacira's performance 'measurably improved' following the launch of its 5x30 strategy and that the board has been proactive in refreshment and governance.
- ISS stated the dissident has 'not presented a compelling case for change' and that its nominees lack public company board experience.
- Glass Lewis previously also recommended supporting Pacira's nominees.
- Goldman Sachs is acting as financial advisor and Perkins Coie as legal counsel to Pacira.
Financial Impact
No financial figures disclosed in this filing. The outcome of the proxy contest could influence strategic direction and capital allocation, but no deal values or financial metrics are provided.
Risk Factors
- Dissident DOMA Perpetual may still win board seats if institutional voting diverges from proxy advisor recommendations.
- Continued activist pressure could distract management or force a sale at an inopportune time.
- The contested election creates near-term uncertainty around strategic direction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-039589 |
| Document: 0001628280-26-039589-index-headers.html | 0001628280-26-039589 |
| Document: 0001628280-26-039589-index.html | 0001628280-26-039589 |
| Document: 0001628280-26-039589.txt | 0001628280-26-039589 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access